AM-Pharma BV
- Biotech or pharma, therapeutic R&D
AM-Pharma develops ilofotase alfa as two distinct products 1) in the rare disease Hypophosphatasia (HPP) and 2) in Cardiovascular associated Renal Damage (CSA-RD). In HPP clinical proof of concept has been achieved and preparations of the next clinical ph2/3 trial are ongoing. In CSA-RD a ph2 study in patients undergoing cardiac surgery is currently enrolling with the aim to prevent renal damage. This study will read out around end of this year at which time we will seek a partner.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}